Fields and Ulcer-Derived Fibroblasts

The term PEMF covers different field parameters. A finding for one frequency, exposure and preparation cannot be assumed to hold for every device or inflammatory condition.

A specific laboratory experiment

Costantini and colleagues studied pulsed radiofrequency electromagnetic-field exposure in primary human fibroblasts taken from venous leg ulcers. They measured proliferation, scratch migration, cytokine gene expression and redox endpoints. These are cellular measurements in vitro. They do not establish patient wound closure, a general reduction in inflammatory cytokines in people or a beneficial nitric-oxide response.

Why dose matters

Interpreting any exposure study requires knowing frequency, intensity, waveform, duration, tissue and measured endpoint. An algorithm that adjusts dose is a proposed design, not proof that it can find a therapeutic dose. A trial of such a system would need a defined comparator, exposure checks, adverse-event monitoring and condition-specific patient outcomes.

The fibroblast experiment cannot justify claims about long COVID, traumatic brain injury, Crohn's disease, oncology or infection. Those conditions require their own sources and controlled investigations. This distinction is more useful than treating “inflammation” as a single transferable indication.

Linking PEMF exposure to inflammation and outcomes Specify field parameters and exposure

Measure inflammatory responses

Test clinical relevance for a defined condition

What the linked references do not establish: The linked pulsed-radiofrequency study examines ulcer-derived fibroblasts, not clinical efficacy across inflammatory diseases.